Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2023 November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights "With regulatory approvals in Japan and Europe, EPKINLY/TEPKINLY is the first Genmab- owned medicine to become available to patients outside of the United States. In addition to being an important milestone for Genmab, these approvals mark an important milestone for patients in these territories who are in need of ...

Company Participants expansions? I know the second-line Phase 3 trial, I believe, is fully enrolled now. And you also started the firstline DLBCL trial recently. Just curious sort of how we should think about the pace of possible label expansions into larger markets. And then a follow-up. Your competitor, Roche, is marketing sort of this fixed duration treatment aggressively for their CD20 bispecific antibodies. Just curious if that is something that is under consideration for EPKINLY as well or if you're s ...

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2023 August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights "The U.S. FDA approval of EPKINLY as the first bispecific antibody to treat adults with relapsed or refractory DLBCL was an important milestone both for Genmab and for patients in need of an innovative treatment option administered subcutaneously. We would like to thank the patients and investigators who took part in the EPCORE ...

Genmab A/S (GMAB) Q1 2023 Earnings Conference Call May 10, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Conference Call Participants Michael Schmidt - Guggenheim Securities Peter Welford - Jefferies Emily Field - Barclays Bank Rajan Sharma - Goldman Sachs Group James Gordon - JPMorgan Chase & Co. Matthew Phipps - William Blair & Company Yaron Werber - TD Cowen Asthika Goonewardene - Truist Securities Peter Verdult - Citigroup Operator Hello ...

Exhibit 99.1 Genmab Announces Financial Results for the First Quarter of 2023 May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights ● Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million "In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie In ...

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Matthew Harrison - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Jonathan Chang - SVB Securities Elizabeth Walton - Crédit Suisse A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 GENMAB 2022 ANNUAL REPORT Table of Contents | MANAGEMENT'S REVIEW | | | --- | --- | | Our Vision | 2 | | Chair's Statement | 2 | | Letter from the CEO | 3 | | 2022 at a Glance | 4 | | Consolidated Key Figures | 6 | | 2023 Outlook | 9 | | Our Strategy | 11 | | Who We Are | 13 | | Business Model | 14 | | Research and Development Capabilities | 15 | | Enhancing Commercialization Capabilities to Bring Our Innovations to Patients | 16 | | Antibody Discovery and Development | 17 | | Products and Tech ...

Quarter End Results Period Ended September 30, 2022 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including develop ...

Genmab A/S (GMAB) Q3 2022 Earnings Conference Call November 9, 2022 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Pagano – Chief Financial Officer Tahi Ahmadi – Chief Medical Officer Conference Call Participants Wimal Kapadia – Bernstein Jonathan Chang – SVB Securities Peter Verdult – Citi Paul Jeng – Guggenheim Partners Peter Welford – Jefferies Emily Field – Barclays Elizabeth Walton – Credit Suisse Michael Novod – Nordea Asthika Goonewardene – Truist Securities Zoe ...